Adaptive Biotechnologies

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Adaptive Biotechnologies reports solid Q1 revenue and optimistic growth outlook

Adaptive Biotechnologies reiterates full year revenue guidance of $205 million to $215 million, with over 50% growth in clonoSEQ test volume and MRD regulatory milestones expected. The company is focused on organic growth, potential incremental paths, and scaling infrastructure for a fully personalized approach in their internal pipeline.

ADPT reports 12% revenue growth, focuses on MRD and Immune Medicine

ADPT demonstrated strong revenue growth driven by MRD and Immune Medicine businesses. While facing challenges in MRD Pharma growth and regulatory milestones, the company is focused on leveraging opportunities in disease-specific target identification and Epic integration.

Adaptive Biotechnologies reports Q3 revenue decline, focuses on maximizing potential

Adaptive Biotechnologies is focusing on maximizing the potential of their MRD and Immune Medicine businesses. They are confident in the potential profitability of the MRD business by 2025 and are actively identifying novel targets in autoimmunity, with a focus on multiple sclerosis. The company is also making strides towards achieving their long-term ASP target of $1,600 in 2027.

Adaptive Biotechnologies reports Q4 revenue growth, focuses on MRD expansion

Adaptive Biotechnologies had a mixed Q4 performance with growth in MRD revenue but a decline in Immune Medicine revenue. The company aims to enhance MRD penetration, improve margins, and advance Immune Medicine efforts. Strategic initiatives and partnerships are in place to drive future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.

CNX Resources

Barrick Gold

This natural gas stock, blood diagnostic company, and gold miner have caught the eye of some of the top investors.

Three Stocks the World's Best Investors Are Buying Right Now.

Coty

Freeport-McMoRan

Despite a strong day for the market, these stocks lagged behind.

Why Freeport-McMoRan, Coty, and Adaptive Biotechnologies Slumped Today

Adaptive Biotechnologies had a heck of a first day as a public company.

Big debut: Shares of Adaptive Biotechnologies rise 100% on first day as public company

Microsoft

Microsoft benefits from an exclusive cloud deal from Adaptive and a stake in the company.

Microsoft is cashing in on the biggest biotech IPO of 2019

Adaptive Biotechnologies Corp. (NASDAQ: ADPT) entered the market with a bang on Thursday.

Adaptive Biotechnologies Enters the Market With a Bang

BridgeBio Pharma Inc

Adaptive Biotechnologies Corp. shares rocketed 96% in their first ten minutes of trade Thursday, after the company priced its initial public offering above its price range.

Adaptive Biotech and BridgeBio shares rocket higher on their first day of trade

Adaptive Biotechnologies made its public debut on Thursday morning, opening at $39.01 after being priced at $20 per share.

Adaptive Biotechnologies Opens Above IPO Price

News for Adaptive Biotechnologies Stock (ADPT)